Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy

This publication has 92 references indexed in Scilit:

• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
  New England Journal of Medicine, 2010
• TH17 cells in tumour immunity and immunotherapy
  Nature Reviews Immunology, 2010
• Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
  Cancer, 2010
• CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
  Proceedings of the National Academy of Sciences, 2008
• CTLA-4 blockade increases IFNγ-producing CD4 ⁺ ICOS ^hi cells to shift the ratio of effector to regulatory T cells in cancer patients
  Proceedings of the National Academy of Sciences, 2008
• CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
  Clinical Cancer Research, 2008
• Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
  Proceedings of the National Academy of Sciences, 2008
• Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
  Cancer Immunology, Immunotherapy, 2006
• Regulatory T cells, tumour immunity and immunotherapy
  Nature Reviews Immunology, 2006
• Checkpoint Blockade in Cancer Immunotherapy
  Published by Elsevier ,2006